Kurlan R, Kim M H, Gash D M
Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14642.
Ann Neurol. 1991 Jun;29(6):677-9. doi: 10.1002/ana.410290618.
We studied rhesus monkeys with hemiparkinsonism or bilateral parkinsonism produced by unilateral or bilateral intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Using a standardized clinical rating scale, 4 hemiparkinsonian monkeys showed a 13 to 56% (mean, 36%) spontaneous improvement during an observation period of up to 25 weeks. Generally, recovery leveled off after 14 weeks. Four bilaterally parkinsonian monkeys showed a 5 to 42% (mean, 22%) improvement over a period of up to 30 weeks. Our findings emphasize that spontaneous recovery is a potentially confounding characteristic of this monkey model when used for assessing novel antiparkinsonian therapies.
我们研究了通过单侧或双侧颈内动脉注射1-甲基-4-苯基-1,2,3,6-四氢吡啶诱导产生偏侧帕金森病或双侧帕金森病的恒河猴。使用标准化临床评分量表，4只偏侧帕金森病猴在长达25周的观察期内出现了13%至56%（平均36%）的自发改善。一般来说，14周后恢复趋于平稳。4只双侧帕金森病猴在长达30周的时间里出现了5%至42%（平均22%）的改善。我们的研究结果强调，当用于评估新型抗帕金森病疗法时，自发恢复是该猴模型一个潜在的混杂特征。
